Caribou Biosciences gets FDA IND clearance for CB-012 allogeneic CAR-T in r/r AML

Caribou Biosciences, Inc.

FDA cleared IND for CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy for relapsed/refractory AML.
AMpLify Phase 1 trial planned to start patient enrollment by mid-2024; first dose level at 25×10^6 CAR-T cells.
CB-012 is the first allogeneic CAR-T with both PD-1 checkpoint disruption and B2M–HLA-E immune cloaking.
CB-012 is Caribou's third off-the-shelf CAR-T therapy to enter clinical development.
AML has ~20,380 new US cases in 2023; median survival for r/r AML is typically <7 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.